A combination product comprising an isolated strain of Bifidobacterium NCIMB 41003 and another strain which does not adversely interact with Bifidobacterium NCIMB 41003 improves gastrointestinal symptoms associated with IBS and improves one or more of mood, stress, anxiety, sleep quality and depression associated with LBS.

The present invention provides a new system with emerging properties in the form of a mixture or composition and the use of the same in the treatment or in assisting the treatment of the metabolic syndrome or one or more symptoms related to it.

The present invention provides a new system with emerging properties in the form of a mixture or composition and the use of the same in the treatment or in assisting the treatment of the metabolic syndrome or one or more symptoms related to it.

Disclosed are methods of reducing the incidence of necrotizing enterocolitis in an infant, toddler, or child using nutritional compositions including human milk oligosaccharides. The nutritional compositions including the human milk oligosaccharides are effective in reducing inflammation and the incidence of inflammatory diseases.

Disclosed are methods of reducing the incidence of necrotizing enterocolitis in an infant, toddler, or child using nutritional compositions including human milk oligosaccharides. The nutritional compositions including the human milk oligosaccharides are effective in reducing inflammation and the incidence of inflammatory diseases.

The present invention generally relates to the field of probiotic bacteria. In particular, it relates to methods for treating or preventing functional GI disorders comprising administering Bifidobacterium longum, such as Bifidobacterium longum ATCC BAA-999.

The present invention generally relates to the field of probiotic bacteria. In particular, it relates to methods for treating or preventing functional GI disorders comprising administering Bifidobacterium longum, such as Bifidobacterium longum ATCC BAA-999.

The present invention generally relates to the field of probiotic bacteria. In particular, it relates to methods for treating or preventing functional GI disorders comprising administering Bifidobacterium longum, such as Bifidobacterium longum ATCC BAA-999.

The present invention generally relates to the field of probiotic bacteria. In particular, it relates to methods for treating or preventing functional GI disorders comprising administering Bifidobacterium longum, such as Bifidobacterium longum ATCC BAA-999.

The use of cholecalciferol is described as an active agent in the treatment of celiac disease, in the reduction of intestinal villous atrophy, and in the protection and regeneration of the intestinal epithelium. Also described are pharmaceutical compositions or food supplements, as well as foods for celiacs, including cholecalciferol and suitable excipients for use in the treatment of celiac disease, in the reduction of intestinal villous atrophy and in the protection and regeneration of the intestinal epithelium.